Mount Sinai Hospital
His primary areas of study are Immunology, Antigen, Pharmacology, Airway resistance and Bronchoconstriction. His Immunology study combines topics in areas such as Bronchoalveolar lavage and Histamine. William M. Abraham interconnects CD49d and Antibody in the investigation of issues within Antigen.
His Pharmacology research includes themes of Endocrinology, Carbachol, Internal medicine, Cystic fibrosis and Mucociliary clearance. His work carried out in the field of Airway resistance brings together such families of science as Marine toxin, Intensive care and Heparin. The various areas that William M. Abraham examines in his Bronchoconstriction study include Inhalation and Red tide.
William M. Abraham mostly deals with Immunology, Pharmacology, Bronchoconstriction, Internal medicine and Antigen. His Immunology research is multidisciplinary, relying on both Bronchoalveolar lavage and Airway. His studies in Airway integrate themes in fields like Asthma and Respiratory system.
His studies deal with areas such as Receptor, Antagonist, Cystic fibrosis, Heparin and Mucociliary clearance as well as Pharmacology. His Bronchoconstriction study deals with Histamine intersecting with Mast cell. In his study, which falls under the umbrella issue of Internal medicine, Mucus is strongly linked to Endocrinology.
William M. Abraham mainly investigates Pharmacology, Immunology, Asthma, Airway and Karenia brevis. His Pharmacology study combines topics in areas such as Mucus, Cystic fibrosis, Heparin and Lung, Mucociliary clearance. In general Immunology, his work in Bronchoconstriction and Antigen is often linked to Syk linking many areas of study.
His Bronchoconstriction study combines topics from a wide range of disciplines, such as Receptor, Antagonist, Prostaglandin and Allergic inflammation. In his research on the topic of Antigen, Histamine, Oligosaccharide and Eosinophil is strongly related with Airway resistance. The concepts of his Airway study are interwoven with issues in Inflammation and Pathology.
His scientific interests lie mostly in Pharmacology, Mucus, Immunology, Cystic fibrosis and Karenia brevis. His Pharmacology study incorporates themes from Receptor, Chemotaxis, Antagonist and Ex vivo. His research in Mucus focuses on subjects like Airway, which are connected to Neutrophil elastase.
His Immunology study integrates concerns from other disciplines, such as Inhalation and Late phase. In Lung, William M. Abraham works on issues like Endocrinology, which are connected to Internal medicine. His work deals with themes such as Gastroenterology, Antigen, Antigen challenge and Allergic inflammation, which intersect with Bronchoconstriction.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Literature Review of Florida Red Tide: Implications for Human Health Effects.
Barbara Kirkpatrick;Lora E. Fleming;Dominick Squicciarini;Lorrie C. Backer.
Harmful Algae (2004)
Alpha 4-integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep.
W M Abraham;M W Sielczak;A Ahmed;A Cortes.
Journal of Clinical Investigation (1994)
Tryptase inhibitors block allergen-induced airway and inflammatory responses in allergic sheep.
James M. Clark;William M. Abraham;Cindy E. Fishman;Rosanna Forteza.
American Journal of Respiratory and Critical Care Medicine (1995)
The porcine lung as a potential model for cystic fibrosis.
Christopher S. Rogers;William M. Abraham;Kim A. Brogden;John F. Engelhardt.
American Journal of Physiology-lung Cellular and Molecular Physiology (2008)
The Lactoperoxidase System Functions in Bacterial Clearance of Airways
Cynthia Gerson;Juan Sabater;Mario Scuri;Mario Scuri;Aliza Torbati;Aliza Torbati.
American Journal of Respiratory Cell and Molecular Biology (2000)
Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).
Claudio F. Sturino;Gary O'Neill;Nicolas Lachance;Michael Boyd.
Journal of Medicinal Chemistry (2007)
Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis.
B. R. Yerxa;J. R. Sabater;C. W. Davis;M. J. Stutts.
Journal of Pharmacology and Experimental Therapeutics (2002)
Inhaled tryptase causes bronchoconstriction in sheep via histamine release.
Jussara F. Molinari;Mario Scuri;William R. Moore;James Clark.
American Journal of Respiratory and Critical Care Medicine (1996)
Review of Florida Red Tide and Human Health Effects.
Lora E. Fleming;Barbara Kirkpatrick;Lorraine C. Backer;Cathy J. Walsh.
Harmful Algae (2011)
Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor.
Christine Brideau;Chi-Chung Chan;S. Charleson;Deschenes Denis.
Canadian Journal of Physiology and Pharmacology (1992)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: